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The incidence of melanoma has risen over the past
30 years in most white populations.1 2 However, in
some parts of the world incidence rates are stable or
falling. Although large scale primary prevention
programmes such as public health education cam-
paigns aimed at reducing exposure to sun may lead to
reduced incidence, such programmes have not yet
been proved effective. However, melanoma is highly
amenable to secondary prevention through early
detection. Being able to recognise a melanoma early
is an important skill for primary healthcare practi-
tioners. In this first article of a two part series on
melanoma, we examine the evidence on the genetic
epidemiology of melanoma and outline the complex
interactions between incidence,mortality, and survival
trends; we also discuss the evidence for prevention.
How common is melanoma?
Althoughmelanoma remains a relatively rare tumour,
many European countries show an annual increase in
incidence above 2%; in some northern European
countries, however, no significant increase has been
observed.1 Between 1992 and 2005, the annual
increase in incidence rates of melanoma in the United
States was 2.3% for all races and 2.8% in white
populations.3 Queensland in Australia had an increase
in incidence of 1.4% for males and 0.7% for females
during 1982 to 2001.4Most recent incidence data show
that in some parts of the US, Australia, and the United
Kingdom, incidence of melanoma has reached a
plateau and even started to decrease.3 5
Should we be concerned by a rising incidence of
melanoma?
Examining incidence, mortality, and survival trends
for melanoma together can produce a clear picture of
the scale of theproblem. Incidencehasbeen inflatedby
early lesions that have little potential to spread and
have a low impact on mortality.6 In countries with
health education campaigns related to skin cancer,
much of the rise in incidence can be attributed to very
thin melanoma lesions or melanomas in situ.
In Australia, for example, an epidemiological study
that reviewed cancer registries showed that the rate of
increase of melanoma in situ has been about 9% a year
compared with only 2.8% for invasive melanomas.2
Over the same period the incidence of thinmelanomas
has increased faster than that of thick tumours, which
have not becomemuchmore common.2Although thin
lesions are diagnosedonaverage five to 10years earlier
than thick ones, this does not necessarily suggest that
they aredetected shortlybefore theybecome invasive.2
Earlier diagnosis is more likely to reflect a trend in
younger patients attending screening.
In contrast with the data on rising incidence,
mortality curves for melanoma have been fairly flat
over the past 30 years in most white populations and
have even begun to fall in the US, Australia,
Scandinavia, and the UK.17 Early melanomas (often
in situ tumours) are increasingly being excised, and
comparisons of incidence and mortality data suggest
that many borderline lesions may never progress if left
alone.2
Who gets melanoma?
The mean age of presentation with melanoma is about
55 years, but this may vary according to thickness and
histological subtype.3 Superficial spreading melano-
mas, usually thinner tumours, are seen in younger
individuals, whereas nodular melanoma and lentigo
maligna melanoma tend to affect older individuals.
Men and women are generally equally likely to be
diagnosed with melanoma, but in some countries a
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slight female preponderance is seen.1 The most
common site for women is the legs and for men the
trunk.8 9 That the difference is attributable to different
patterns of sun exposure inmen andwomen is unlikely
because a difference in site according to sex is seen in
countries with differing sun exposure and clothing
habits. For example, the site distribution of melanoma
according to sex is similar in Australia, the UK, and
Israel despite different skin exposure habits between
the three countries.10 Site differences according to sex
are likely to reflect genetic differences as naevi are also
differently distributed between boys and girls from an
early age.11
What are the risk factors for melanoma?
Exposure to sun
Although sun exposure has long been suspected to be a
risk factor for melanoma, the relation between sun
exposure andmelanoma is complex.Theevidence that
sun exposure may be associated with melanoma is
apparent when comparing incidence in Australia and
sunny parts of the US with Europe.3 The incidence of
melanoma is three to four times higher in Queensland,
Australia, than in the UK.2 However, a significant
association between sun exposure behaviour and
melanoma is less easy to show in a case-control
setting.12 13 A meta-analysis of melanoma case-control
studies found low relative risks associated with various
measures of exposure to ultraviolet radiation, and the
relation with sunshine was not dose dependent.14
Sharp, short bursts of acute exposure in childhood,
and severe sunburn, were most strongly associated
with melanoma. However, cumulative occupational
exposure seemed to be protective in some white
populations. Odds ratios associated with sun exposure
are often no longer significant after adjustment for skin
type, which supports a hypothesis that host response to
ultraviolet radiation ismore important thandose of sun
exposure.
Use of sun beds
Melanoma is controversially associated with use of
sunbeds. Some epidemiological studies have not found
sunbed use to be a significant risk, whereas others have
found small increased risks.13 15-17
Sunbed use seems to be most detrimental before the
age of 20, and current recommendations are that
sunbeds should be avoided, especially in relating to
premature skin ageing.17 Individuals with red hair and
freckles, or multiple atypical naevi, with or without a
family history of melanoma, should avoid sunbeds
since their risksofdevelopingbothmelanomaandnon-
melanoma skin cancer are already significantly
increased.18
Skin pigmentation
Having fair skin with a poor ability to tan, or a freckled
complexion with or without red hair, doubles a
person’s risk of melanoma.18 Polymorphisms in the
melanocortin 1 receptor (MC1R) gene have been
linked to fair skinand redhair andhavebeenassociated
with an increased risk of melanoma.19 20
Melanomas present rarely in non-white people, in
whom the incidence is 10 to 20 times lower than in
white people.3 Body site and histological subtypes
differ between white and non-white people. The latter
more frequently present with lentiginous and nodular
Fig 1 | Atypical naevus with diameter of more than 5 mm and
hazy border
Fig 2 | Superficial spreading melanoma with a well demarcated
edge and irregular pigmentation
Box 1 What to look for when a naevus changes
Change in size
Naevi may change in size over years, but any change over weeks or months is suspicious
Change in colour
Melanomasoften show irregular pigment in a lesion,with shadesof black, brown, grey, and
pink. In nodular melanoma the lesion is often black throughout. Rarely a melanoma can
present as a non-pigmented red nodule (amelanocytic melanoma); this is more likely on
hands and feet
Change in outline
Melanomas often show a geographical outline with a sharp cut-off from normal skin
Itching
Itching may be a late sign and is often unreliable as many benign naevi intermittently itch
Bleeding
Bleeding is also a late sign and is often present in advanced melanoma
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melanoma on the palms and soles and rarely on other
parts of the body.3 21
Naevi
Naevi are the most powerful predictor of risk of
melanoma. A meta-analysis of observational studies
found that an individual who has more than 100
common naevi or more than two atypical naevi has a
fivefold to 20-fold increased risk of melanoma.22 Unlike
melanoma, atypical naevi (fig 1) are usually symmetrical
and do not have a sharp edge with geographical border;
asymmetry and sharp edged borders are clear signs of
malignant transformation (fig 2). 23 Furthermore, naevi
remain static whereas melanoma change in size, shape,
or colour over weeks or months.
In younger individuals atypical naevi on the trunk
and limbs aremore predictive of superficialmelanoma
than of nodular melanoma or lentigo maligna mela-
noma, which affect older individuals with more sun
damage and fewer naevi.24w1 The presence of multiple
common naevi and atypical naevi denotes the pheno-
type for atypicalmole syndrome, whichmay indicate a
genetic susceptibility to melanoma (boxes 1 and 2).
This phenotype is found in about 2% of a healthy
population in the UK.w2
Two twin studies suggest that naevi are under
considerable genetic control, with a 60% concordance
in numbers of naevi in identical twins.w3 w4 A cross
sectional twinstudyofover2000individual twinsshowed
that naevi undergo senescence with age, with a decrease
in numbers from the age of 30 to 40 years, but that in
patients with the atypical mole syndrome the number of
naevi can remainhigh aftermiddle age.w3 Inpatientswith
the syndrome,naevi arealsooften foundonunusual sites,
such as scalp, buttocks, feet, hands, and irises.w5
Solar keratoses
Solar keratoses carry a relative risk for melanoma of 2
to 4.w6 w7 The presence of naevi and solar keratoses is
often mutually exclusive, suggesting different path-
ways to melanoma—via an excess of naevi in younger
individuals or via chronic sun damage and cumulative
sun exposure in older subjects.24w6 w7
Family history of melanoma and genetic factors
Five to ten per cent of individuals withmelanoma have
a family history of melanoma.w5 In families with
melanoma, affected individuals often have the atypical
mole syndrome phenotype (fig 3). About a quarter of
all families with melanoma have been linked to
mutations in the tumour suppressor gene CDKN2A/
p16 on chromosome 9p21, which affects the germline
and is therefore transmitted through generations.w8
Mutation screening outside the research setting is not
recommended as the prevalence of germline
CDKN2A mutations is very low and does not alter
management. 23 In some families with melanoma,
susceptibility to someother cancers—such as pancreas,
brain, and breast cancer—is increased, so taking a
thorough family history of cancers in patients with
melanoma is important.w9
Hormonal factors
Mortality studies have shown that women have
thinner tumours and survive melanoma better than
men even after adjustment for Breslow thickness,
ulceration, and body site, which suggests that there
may be X linked variable gene expression or
hormonal factors affecting melanoma survival.9w10
Anecdote reports melanoma behaving aggressively
during pregnancy and metastases manifesting
themselves during pregnancy. However, a meta-
analysis that examined data on over 5000 female
participants showed that risk of melanoma was
not affected by pregnancy, oral contraception, or
hormone replacement.w11
Box 2 Phenotype for atypical mole syndrome
What are the features of the phenotype?
 More than 100 common naevi (≤2 mm in diameter)
 More than two atypical naevi (≥5 mm in diameter)
 Naevi on unusual sites such as breasts in females,
buttocks, scalp, ears, dorsum of feet
When the phenotype is present
 If there is alsoa family history ofmelanomaormultiple
cancers, referral to a dermatologist is recommended
 Removal of atypical naevi just to confirm histological
dysplasia is not helpful. Lesions should be removed
only if early melanoma is suspected and only by an
experienced clinician
Fig 3 | Atypical mole syndrome with many atypical naevi on
trunk
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Can melanoma be prevented?
Primary prevention—benefits and harms
Health education campaigns aimed at reducing
people’s exposure to sun began in Australia in the
1980s and were soon adopted elsewhere in the world.
There is, as yet, no direct evidence that reducing sun
exposure has had an effect on melanoma incidence.
Some commentators have suggested that the slowing
down and even downturn in incidence inmelanoma in
some parts of the world may be due to the health
education programmes, but the downturn has been
seen in parts of the world where levels of sun exposure
and public health campaigns vary.4 Furthermore, the
lag time between change in behaviour and the recent
downturns in incidence may have been too short for
health education to be the sole explanation.
A recent BMJ editorial raised a concern that drastic
reduction of sun exposure in temperate climates may
have an impact on health because of low vitamin D
levels.w12 Vitamin D is important for bonemetabolism
but has also been shown to have protective effects
against inflammation, cancer, psychiatric diseases, and
autoimmune disease. Avoiding sunburn and excessive
sun exposure without protection seems to be the most
important message in skin cancer prevention without
advocating keeping away from the sun altogether.w13
More research is needed in this field to understand not
only the relation betweenmelanoma and sun exposure
but also the potential detrimental effects of vitamin D
deficiency after sun avoidance.
Secondary prevention—early identification and treatment
Melanoma is amenable to secondary prevention as
tumours are highly visible with a good prognosis if
detected early. Secondary prevention is a more
efficient way to reduce mortality from melanoma
than primary prevention as the latter has not yet been
proved to reduce incidence or mortality significantly.
However, for secondary prevention to be successful,
educating the public and health professionals to
recognise melanoma early is crucial.
Is there any benefit in screening?
Screening strategies have not yet been formally
assessed as the design of such trials is difficult.
Individuals with multiple atypical naevi, a family
history of melanoma, and/or multiple cancers should
be referred to a dermatologist for screening as their risk
of melanoma is significantly increased.23 However,
melanoma is an uncommon cancer and population
screening may not yield a substantial number of cases.
Public health campaigns depicting melanoma as a
serious killer are no longer accurate as more than 80%
of patients with melanoma now survive their disease,
with most melanomas being treated with relatively
minor surgery alone.1 7 Concern has been expressed
that aggressive public health campaigns lead to anxiety
related increases in the excision of benign lesions and
melanoma in situ.w14 In Australia, where melanoma
screening is most active, a sharp rise in melanoma in
situ and very thin melanomas has been observed over
the past 10 years, thus inflating incidence figures.2
There is certainly a need to educate the public on what
to look for when a mole changes, while avoiding
generating anxiety and the subsequent removal of too
many benign lesions.
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ADDITIONAL EDUCATIONAL RESOURCES
Resources for patients
 GenoMEL (www.genomel.org/english/patientInformation.htm)—GenoMEL (Melanoma
Genetics Consortium) has available a booklet, Melanoma: Dealing with the Diagnosis
 Royal College of Physicians. Prevention, diagnosis, referral and management of
melanoma of the skin. Concise guideline No 7. www.rcplondon.ac.uk/pubs/brochure.
aspx?e=216
 British Association of Dermatologists (www.bad.org.uk/public/leaflets/melanoma.
asp)—Leaflet and contacts for support
 Cancer Research UK (www.cancerhelp.org.uk/help/default.asp?page=2788)—Advice
on melanoma
Resources for health professionals
 GenoMEL (www.genomel.org/english/physicianInformation.htm)—GenoMEL
(Melanoma Genetics Consortium) gives information and references on melanoma
 National Cancer Institute. Surveillance epidemiology and end results. (http://seer.
cancer.gov/faststats/selections.php?
run&output=2&data=1&statistic=2&year=200802&race=2&sex=1&age=1&series=
=1&statistic=2&year=200802&race=2&sex=1&age=1&series=cancer&cancer=53)
 Cancer Research UK (http://info.cancerresearchuk.org/cancerstats/types/skin/
incidence/)—Gives statistics on skin cancer
 Information Services Division Scotland (www.isdscotland.org/isd/1048.
html#Malignant%20melanoma%20of%20the%20skin)—Data, reports, and
factsheets.
 MelanomaMolecularMapProject (www.mmmp.org)—Six interconnecteddatabanks for
the interactive collection, update, and consultation of the translational and clinical
information on melanoma biology and treatment
 National Institute for Health andClinical Excellence.Skin tumours includingmelanoma.
(Cancer service guidance.) 2006. www.nice.org.uk/Guidance/CSGSTIM
 Department of Health. Guidelines for the appointment of general practitioners with
special interests in thedeliveryof clinical services:dermatology. 2003.www.dh.gov.uk/
en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/
DH_4008233
SUMMARY POINTS
The incidence of melanoma is rising, but most of the rise is
caused by very thin melanomas
Themost powerful risk factor formelanoma is the number of
naevi
There are two phenotypic pathways to melanoma: via naevi
or via sun damage
Melanomamortality has been relatively stable over the past
30 years
A reduction in people’s exposure to sun has not led to a
significant reduction in the incidence ofmelanoma, and sun
avoidance may be detrimental; secondary prevention with
early detection of melanoma saves lives
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The peril of treating your progeny
Lucy was in her 30s with a promising career as an internet
programmer and a lucrative offer towork inAsia. She also
zealously volunteered her time and service to an inter-
national health organisation. She was the daughter of a
practising doctor, who was successful in his own right.
However, a recent history of headaches and photo-
phobiahad increased in intensity to thepointofLucybeing
hospitalised. The results of imaging of the brain,
performed at a hospital where her father worked, were
reported as within normal limits, and analysis of her
cerebrospinal fluid revealed a fewmononuclear cells. She
was subsequently discharged with analgesics and a
diagnosis of aseptic meningitis.
Her symptoms progressed, however, and she became
virtually blind. An ophthalmologist diagnosed progres-
sive outer retinal necrosis fromherpes zoster infection and
immediately ordered an HIV serology test, which
produced a positive result. This also showed a high
virologic load and a very lowCD4 cell count indicative of
advanced disease. Her cerebrospinal fluid obtained at her
previous hospital admission showed the presence of
varicella zoster virus. Her retinal necrosis was extensive,
and—despite highly active antiretroviral therapy, intra-
ocular and systemic foscarnet and ganciclovir, and a
silicon tamponade to stabilise her retina—she ultimately
became completely blind.
Lucy for many years had had a history of sinopulmon-
ary infections and an episode of multidermatomal
shingles, and these infections were either observed or
treated presumptively with antibiotics by her father or his
associates. Lucy is now considering her vocational goals as
she had to relinquishher career as an internet programmer
and is adjusting to the emotional trauma and physical
limitations of her blindness.
It is easy to be judgmental in hindsight, but her father,
filled with regret and guilt, struggled to hold back the tears
as he said to me, “My duty was to be her father, not her
doctor.”
I am now the father of two small children, and those
words of Lucy’s father echo strongly in my own
philosophy towards their health. My emotional connec-
tion with my children will always preclude an objective
and optimal assessment. They have their own family
practitioner; not one who is a close friend of mine but a
doctor who is highly recommended by my neighbours.
Suran Fernando clinical immunologist, Royal North Shore Hospital,
St Leonards, Australia
suran@tpg.com.au
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